Neal has been President & CEO and a Director for six life science businesses guiding them to milestone achievement or exit. He began his career at Wyeth Pharmaceuticals where he achieved notable successes in both large division and early stage business responsibilities. Neal has over 30 years as a top executive with a successful history of building, running and exiting entrepreneurial and complex global companies.

OUR PEOPLE

Neal Koller, Chairman & CEO

Neal Koller, Chairman & CEO
Neal has been President & CEO and a Director for six life science businesses guiding them to milestone achievement or exit. He began his career at Wyeth Pharmaceuticals where he achieved notable successes in both large division and early stage business responsibilities. Neal has over 30 years as a top executive with a successful history of building, running and exiting entrepreneurial and complex global companies.

Steven Pentelnik, President
Steven has over 30 years of experience at Procter & Gamble (P&G). At P&G, he was responsible for its $1 billion early-stage technology portfolio and was a global manager of its $750 million Beauty Care Products business. Post P&G, he held executive responsibility for developing three start-up companies in medical devices and life sciences. Steven has a highly successful track-record in bringing new products to market.

Steven Pentelnik, President
Steven has over 30 years of experience at Procter & Gamble (P&G). At P&G, he was responsible for its $1 billion early-stage technology portfolio and was a global manager of its $750 million Beauty Care Products business. Post P&G, he held executive responsibility for developing three start-up companies in medical devices and life sciences. Steven has a highly successful track-record in bringing new products to market.

Gary Pekoe, PhD, Chief Scientific Officer
Gary has his doctorate degree in pharmacology. He is a thought leader in infectious diseases, skin diseases and cancer. Gary led the team that developed and obtained FDA approval of Bactroban® (mupirocin), the topical drug of choice for MRSA drug resistant skin infections. He has directed multiple pharma/biotech product development programs and founded a strategic regulatory and clinical company focused on early stage innovations. Gary has over 30 years helping develop cutting edge biotechnologies.

Gary Pekoe, PhD, Chief Scientific Officer
Gary has his doctorate degree in pharmacology. He is a thought leader in infectious diseases, skin diseases and cancer. Gary led the team that developed and obtained FDA approval of Bactroban® (mupirocin), the topical drug of choice for MRSA drug resistant skin infections. He has directed multiple pharma/biotech product development programs and founded a strategic regulatory and clinical company focused on early stage innovations. Gary has over 30 years helping develop cutting edge biotechnologies.

Jazmyne Mink, Scientific Researcher
Jazmyne is a dynamic researcher who has developed a broad understanding of the mechanisms of plant-derived compounds in the treatment of serious skin diseases.

Jazmyne Mink, Scientific Researcher
Jazmyne is a dynamic researcher who has developed a broad understanding of the mechanisms of plant-derived compounds in the treatment of serious skin diseases.